Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Sep 15;25(18):5438-5440.
doi: 10.1158/1078-0432.CCR-19-1836. Epub 2019 Jul 17.

Nivo-lution in Mesothelioma

Aaron S Mansfield  1 , Marjorie G Zauderer  2
Affiliations
Comment

Nivo-lution in Mesothelioma

Aaron S Mansfield et al. Clin Cancer Res. .

Abstract

The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.See related article by Okada et al., p. 5485.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Synthetic control groups derived from national mesothelioma registry. Single-arm clinical trial results for rare tumors like mesothelioma could be augmented by contemporaneous synthetic control groups matched for prognostic factors and derived from the national mesothelioma registry that is in development.
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 2019. doi 10.1158/1078-0432.CCR-19-0103. - DOI - PubMed
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636–44 doi 10.1200/JCO.2003.11.136. - DOI - PubMed
    1. Zauderer MG, Tsao AS, Fennell DA, Wong WB, Pattipaka T, Bretscher MT, et al. Patterns of comorbidity, treatment, resource utilization, and referral in malignant pleural mesothelioma patients in the US. J Clin Oncol 2017;35.
    1. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387(10026):1405–14 doi 10.1016/S0140-6736(15)01238-6. - DOI - PubMed
    1. Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013;14(11):1104–11 doi 10.1016/S1470-2045(13)70381-4. - DOI - PubMed

LinkOut - more resources